Department of Medicine, Emory University, Atlanta Veterans Affairs Medical Center, Decatur, GA, USA.
PPAR Res. 2007;2007:18797. doi: 10.1155/2007/18797.
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily that regulate diverse physiological processes ranging from lipogenesis to inflammation. Recent evidence has established potential roles of PPARs in both systemic and pulmonary vascular disease and function. Existing treatment strategies for pulmonary hypertension, the most common manifestation of pulmonary vascular disease, are limited by an incomplete understanding of the underlying disease pathogenesis and lack of efficacy indicating an urgent need for new approaches to treat this disorder. Derangements in pulmonary endothelial-derived mediators and endothelial dysfunction have been shown to play a pivotal role in pulmonary hypertension pathogenesis. Therefore, the following review will focus on selected mediators implicated in pulmonary vascular dysfunction and evidence that PPARs, in particular PPARgamma, participate in their regulation and may provide a potential novel therapeutic target for the treatment of pulmonary hypertension.
过氧化物酶体增殖物激活受体 (PPARs) 是配体激活的转录因子,属于核激素受体超家族,可调节从脂肪生成到炎症等多种生理过程。最近的证据确立了 PPARs 在系统性和肺血管疾病和功能中的潜在作用。目前对肺动脉高压(肺血管疾病最常见的表现形式)的治疗策略受到对潜在疾病发病机制的理解不完整和缺乏疗效的限制,这表明迫切需要新的方法来治疗这种疾病。已经表明,肺内皮衍生介质的紊乱和内皮功能障碍在肺动脉高压发病机制中起着关键作用。因此,以下综述将重点介绍参与肺血管功能障碍的选定介质的证据,以及 PPARs(特别是 PPARγ)参与其调节的证据,这可能为肺动脉高压的治疗提供一个潜在的新的治疗靶点。